Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Actelion Gets Option To Acquire Trophos

by Lisa M. Jarvis
July 26, 2010 | A version of this story appeared in Volume 88, Issue 30

In a deal crafted to mitigate the risk associated with compounds in development, Actelion has paid $13 million for an option to acquire Trophos. If Trophos’ lead compound, olesoxime, produces positive Phase III results in treating amyotrophic lateral sclerosis, Actelion will pay between $160 million and $250 million for the Marseille, France-based biotech firm. Olesoxime is a cholesterol-oxime compound identified by Trophos’ neuronal cell-screening platform. Trophos also has agreed to give Actelion access to its central nervous system assay technology and compound library.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.